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Abstract
Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochro-
mocytomas (PGLs/PHEOs) for von Hippel–Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin 
tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter 
(hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that 
enter the synthesis and storage pathway of catecholamines. Nonspecific methods are not related to the synthesis, uptake, or stor-
age of catecholamines but make use of the tumors’ high glucose metabolism or expression of somatostatin receptors. Consen-
suses and guidelines suggest that metastatic and sporadic PHEOs/PGLs in VHL patients (as in patients with chromaffin tumors 
of yet unknown genotype) should be evaluated first with 18F-dihydroxyphenylalanine (18F-DOPA) positron emission tomogra-
phy/computed tomography (PET/CT). The functional imaging of second choice is 123I-metaiodobenzylguanidine (123I-MIBG) 
for PHEOs in VHL patients. 123I-MIBG, 68Ga-DOTATATE/DOTATOC/DOTANOC PET/CT, or 18F-fluorodeoxyglucose 
(18F-FDG) PET/CT can be a second choice of functional imaging for PGLs in VHL patients.
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Introduction
Pheochromocytomas and paragangliomas (PHEOs/PGLs; 
70 and 30% of tumors, respectively) are rare chromaffin-cell 
neuroendocrine tumors represented by PGLs (developed from 
paraganglia which can be localized from the base of the skull 
to the pelvic floor) and PHEOs (or adrenal paragangliomas) (1, 
2). Intra-adrenal PGLs are termed PHEOs (3); this is according 
to the World Health Organization’s most recent printed endo-
crine tumor classification dating to 2004 (4). This classification 
is still in effect (as a matter of fact initially, in the print version, 
benign intra-adrenal sympathetic PGLs were considered to 
be benign PHEOs (4), whereas more recently all intra-adrenal 
PGLs are termed PHEOs (5–8)). Thus, the terms PHEOs and 
PGLs can be used according to localization to define adrenal 
and extra-adrenal disease, respectively, or otherwise most neural 
crest-derived chromaffin tissue tumors can be acceptably termed 
PGLs (3). Hereditary forms account for 30% of cases (9). The 
prevalence of PHEOs is approximately 1/500,000 and that of 
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PGLs is approximately 1/1,000,000. The incidence of von Hip-
pel–Lindau (VHL) syndrome is estimated to be 1 in 36,000 
births and the prevalence is estimated at 1/53,000 (10, 11). More 
than 500 inherited mutations in the VHL gene have been iden-
tified in people with VHL syndrome. Most often these are mis-
sense mutations in the VHL tumor suppressor gene (usually 
in codon 167; 3p25–26). Subjects with VHL develop heman-
gioblastomas, renal and pancreatic cysts, clear cell renal carci-
nomas, and pancreatic neuroendocrine tumors. Furthermore, 
approximately 25–50% of subjects with VHL syndrome have 
mostly benign PHEO/PGL (less than 5–15% are malignant, and 
slightly less than half of the patients show bilateral adrenal dis-
ease) (10, 12); they can also have sympathetic and head and neck 
PGLs (1). Generally, PGLs secret catecholamines or they can be 
nonsecreting, whereas PHEOs generally secrete catecholamines 
(2). Secreting PGLs (which are associated with the sympathetic 
system) are mainly thoraco-abdominopelvic. Patients with VHL 
and PHEOs/PGLs are considered to secrete predominantly nor-
epinephrine (1). Nonsecreting PGLs are localized at the head 
and neck, and can manifest as asymptomatic masses or with 
symptoms associated with encroachment of nearby structures. 
No validated malignancy marker exists for PGLs (regarding 
about 15% of cases) with the exception of presumed or vali-
dated metastases. Diagnosis is based on clinical examination 
and family history. Young age at diagnosis and presence of mul-
tiple, extra-adrenal, bilateral adrenal, or malignant tumors are 
in favor of a hereditary form. Some authors recommend that 
any patient with a diagnosis of PHEO/PGL can benefit from 
genetic counseling (2). Others suggest a more restrictive coun-
seling: in the case of extra-adrenal localization (PGL), bilat-
eral PHEO, unilateral PHEO, and a family history positive for 
PHEO/PGL, and in any patient under 40 years with unilateral 
PHEO. The mutation research will be oriented according to the 
clinic, biology, and location of the tumor.
The first diagnostic step for PHEO/PGL involves biochem-
ical testing for metanephrines and normetanephrines in blood 
or 24-h urine collections. These two tests have a good sensitiv-
ity >95% with a somewhat lower specificity of about 90–95% 
(2). Initial tumor localization is based on anatomical imaging, 
with computed tomography (CT) or magnetic resonance im-
aging (MRI). The typical appearance of PHEO/PGL is that 
of a spherical or ovoid lesion, with well-delimited tissue, with 
a certain heterogeneity, necrotic zones, and calcifications. The 
administration of a contrast agent according to the type of 
imaging helps to characterize the lesion. Due to the predomi-
nant intra-abdominal location of PHEO/PGL, abdominal and 
pelvic CT/MRI are the first-choice imaging modalities. The 
latter is recommended for patients with metastatic PGL and 
patients who have a contraindication of exposure to radiation 
(pregnant women, age below 25, etc.) (2, 13). Nevertheless, an-
atomical imaging, particularly for extra-adrenal disease, has 
shortcomings and further evaluation is warranted (14).
Further localization evaluation may require functional ex-
ploration by scintigraphy (i.e., nuclear medicine modalities) 
or positron emission tomography (PET) scan. Functional im-
aging is recommended in the baseline evaluation of patients 
with large PHEOs or PGLs, because size is linked with the 
risk of metastatic disease. Genetics also guides the imple-
mentation of functional imaging in the case of patients with 
syndromes known to harbor hereditary/bilateral/metastatic/
malignant disease. Scintigraphy with 123I-metaiodobenzyl-
guanidine (123I-MIBG) remains an examination of choice in 
this indication. On the other hand, Fluorine-18 (18F)-labeled 
fluorodeoxyglucose (18F-FDG) PET/CT would be superior to 
MIBG scintigraphy in the case of a known metastatic tumor.
Few reports have presented data and results of func-
tional imaging on PGLs/PHEOs for VHL patients (Table 1). 
Herein, we briefly review the radiopharmaceuticals that have 
been used clinically for functional imaging on PGLs/PHEOs 
with an emphasis on VHL-associated disease.
Functional imaging in patients with PHEO/PGL
Nuclear medicine localization modalities for chromaffin 
tumors can be specific or non-specific. Specific methods 
make use of the expression of the human norepinephrine 
transporter (hNET) and vesicular monoamine transporters 
(VMATs) by these tumors (13). These transporters permit 
the use of radiolabeled ligands that enter the  synthesis and 
storage pathway of catecholamines. Nonspecific methods are 
not related to the synthesis, uptake, or storage of catecho-
lamines but make use of the tumors’ high glucose metabo-
lism or expression of somatostatin receptors. Ideally, specific 
functional imaging methods should be used first and, if  nega-
tive, nonspecific modalities should then follow, particularly if  
recurrent, metastatic, or malignant disease is suspected (13).
Chromaffin-tumor-specific functional imaging
Meta-iodobenzylguanidine (MIBG) is a catecholamine pre-
cursor that is uptaken by chromaffin cells via hNET. Previous 
studies used iodine-131 (131I) MIBG, which was not very 
helpful in delineating metastatic or extra-adrenal PHEO/
PGL (15, 16). Nowadays, it is labeled with iodine-123 (123I). 
It has no beta particle emission and its radiation exposure is 
low. Its half  life is short (13.2 h) and allows higher doses to 
be injected; its principal emission photon energy (159 keV) 
lies closer to the 140 keV level (that of  99mTc) around which 
gamma cameras are made to operate (at these energies the 
detection efficiency of  scintillation crystal is satisfactory). 
123I-MIBG permits tomographic imaging (single photon 
emission computed tomography (SPECT)). This allows the 
identification of  small lesions that may not be evident on 
planar images. In addition, the combination of  anatomi-
cal and functional information by hybrid SPECT/CT and 
SPECT/MRI imaging may increase the diagnostic accuracy. 
The  sensitivity of  123I-MIBG is 85–88% and 56–76% and 
specificity is 70–100% and 84–100% for chromaffin tumors 
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limited to the adrenals or for extra-adrenal localizations, 
 respectively (17, 18).
Short-lived radioligands are used in PET, permitting 
functional imaging (including tomographic views) with 
higher spatial resolution than that delivered by conven-
tional scintigraphic imaging. Dopamine is a catecholamine 
precursor and PET with 18F- fluorodopamine (18F-FDA) 
has been used with success in imaging adrenal and/or be-
nign PHEOs or metastatic PHEOs/PGLs. The 110-min 
half-life of  18F permits tracers radiolabeled with this nu-
clide to be distributed to centers for diagnostic imaging that 
do not have on-site cyclotrons for preparing radiopharma-
ceuticals. Dihydroxyphenylalanine (DOPA) is converted 
into dopamine and then transported into PHEOs/PGLs 
via the large-type amino acid transporters (mainly LAT-1 
and LAT-2) (19). PET with 18F-DOPA has been used for 
localizing PHEOs (sensitivity is reported at 89–97%) and 
is considered to be very accurate in imaging sporadic dis-
ease (19, 20). An advantage of  18F-DOPA PET over other 
modalities is that it does not show high uptake in normal 
adrenal glands (21).
Non-chromaffin-tumor-specific functional imaging
Functional imaging with PET using 18F-FDG is currently 
widely available. This is a versatile modality that can local-
ize various tumors and aid the staging of neoplastic disease. 
18F-FDG PET is a convenient and accessible modality for 
localizing PHEOs/PGLs that are negative with specific func-
tional imaging modalities (particularly metastatic disease) 
(Figure 1) (22). In patients with succinate dehydrogenase beta 
(SDHB)-associated PHEO/PGL—which are more prone to 
malignant disease—18F-FDG PET has 97–100% sensitivity in 
localizing tumor lesions, whereas the sensitivity of 123I-MIBG 
is 65–80% and that of 18F-FDA PET is 70–88% (23).
The expression of somatostatin receptors (ST-R) is common 
in PHEOs and PGLs (they mainly express type 2—mostly-, 
3 and 5 ST-Rs (24); however, there are discrepancies in the 
Table 1. Selected published reports evaluating functional imaging of PHEO/PGL in VHL (only papers with at least five VHL 
patients were included)
Report Radiopharmaceutical n of VHL patients Results/remarks
Accuracy of localiza-
tion in bilateral adrenal 
disease
Srirangalingam et al. 
(32)
MIBGa 12 Overall accuracy of 
localization: 92%
40%
Rischke et al. (35)
18F-DOPA 19 (with multiple 
disease foci n = 6, with 
metastatic disease 
n = 1)
Sensitivity:
On a per-patient basis: 
89%
On a per-lesion basis: 
89%
–
Kaji et al. (37)
18F-FDA
7 (with bilateral 
 adrenal disease n = 2)
Overall accuracy of 
localization: 100%
100%
123/131I-MIBG Overall accuracy of 
localization: 57%
100%
Weisbrod et al. (40)
18F-DOPAb 52 (with extrapancre-
atic disease n = 15)
Adrenal disease n = 
10, bilateral adrenal 
disease n = 1, neck 
PGL n = 1
–
Taïeb et al. (15) 
131I-MIBG 5 (with bilateral 
adrenal disease n = 3, 
extra-adrenal disease 
n = 1)
Sensitivity:
On a per-patient basis: 
60%
On a per-lesion basis: 
75%
100%
aIn the report there is no distinction between 123I-MIBG and 131I-MIBG. bSubjects were also studied with 18F-FDG PET but no details of 
imaging results or comparisons of imaging modalities’ results were given in the publication.
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 literature and conflicting results have been presented). Oct-
reotide is an octapeptidic somatostatin analog that is chelated 
with diethylenetriaminepentaacetate (DTPA) and labeled with 
indium-111 (111I-Pentetreotide) for ST-R scintigraphy (SRS). 
Although its splenic and renal accumulation is intense, it is 
nevertheless useful for localizing malignant/metastatic PHEOs/
PGLs with a sensitivity approaching 90%. ST-R-based imag-
ing may be less specific than 18F-DOPA PET imaging in the 
evaluation of PHEOs/PGLS (21). Furthermore, false positives 
may be expected in metastatic lymph nodes, meningiomas, 
and inflammation foci (21). Recently, novel 68 Gallium (68Ga)-
DOTA-labeled somatostatin analogs (68Ga-DOTATATE, 
68Ga-DOTANOC, and 68Ga-DOTATOC) have been intro-
duced to clinical PET/CT use; they are reported to have higher 
sensitivity for detecting neuroendocrine tumors compared to 
“classic” SRS (25) (Figure 1). 68Ga-DOTATATE PET/CT was 
better than 18F-DOPA, 18F-FDA PET/CT, CT/MRI, and es-
pecially 18F-FDG PET/CT in imaging patients (n = 22) with 
sporadic metastatic PHEO/PGL (26), or head and neck PGLs 
(sensitivity reported at 93% in a series of 30 patients) (20).
Functional imaging in patients with VHL
Although the literature is rich on the functional imaging of 
PHEOs/PGLs, few reports have presented data and results on 
VHL patients, and the numbers included were small.
The use of MIBG scintigraphy in a woman with VHL 
has changed fundamentally her management, as presented 
Figure 1. Anterior maximum intensity projection images of 68Ga-DOTATATE (A) and 18F-FDG (B) PET/CT of a 48-year-old 
female patient with metastatic PGL; note more foci of uptake with 68Ga-DOTATATE compared to 18F-FDG. (Images courtesy 
of Karel Pacak, MD, PhD, DSc, Section on Medical Neuroendocrinology, NICHD, NIH, Bethesda, MD, USA.)
Ilias I and Meristoudis G.
Journal of Kidney Cancer and VHL 2017; 4(3): 30–36 34
in an older case report, when scintigraphy indicated a met-
astatic PHEO in a lesion initially considered to be a brain-
stem hemangioblastoma (27); PHEO metastases were seen 
with 123I-MIBG in another case report (28). However, sub-
jects with VHL have lower VMATs expression in chromaffin 
tissue, possibly hampering the use of MIBG as an effective 
functional imaging agent (29, 30). Additionally, 123I-MIBG 
uptake was not correlated with either hNET or VMAT 
(VMAT-1 in particular) expression in a series of 62 patients 
with PHEOs/PGLs, including two patients with VHL (31). 
In a comparison between VHL patients and SHDB patients, 
a study found that MIBG was overall positive in 11/12 VHL 
patients but was falsely negative in 3/5 VHL patients with 
synchronous bilateral adrenal PHEOs (32).
In a series of 116 patients with PHEOs/PGLs (and n = 3 
with VHL), imaging with 18F-DOPA PET (lumped together 
in non-SDHx cases) had no false negative results (33). In 
an older series of 52 PHEOs/PGLs patients (and n = 2 with 
VHL, one with nonmetastatic and one with metastatic dis-
ease), PET with 18F-DOPA and 18F-FDA had showed the 
same lesions; both were better than 123I-MIBG in imaging the 
patient with metastatic disease (34). No influence of geno-
type on tumor 18F-DOPA uptake was noted in a PET–PET/
CT study of 101 patients with PHEOs/PGLs; 19/101 were 
VHL patients (in one patient, 18F-DOPA was falsely nega-
tive, and sensitivity and specificity for the modality in VHL 
patients were calculated to be 89%) (35). Interestingly, in a 
study of 34 PHEO patients (of whom n = 3 reported with 
VHL), 18F-DOPA PET/CT had equivocal results for adre-
nal uptake (36). 18F-FDA PET was superior to 123I-MIBG 
in the context of VHL syndrome: in 7/7 VHL patients, all 
their PHEOs were imaged (two patients had bilateral disease) 
with the former modality, whereas the latter was positive in 
4/7 patients (37).
PGLs in VHL patients are usually positive on 18F-FDG 
PET examinations (38); this positivity is probably more due 
to glucose transporters’ overexpression than increased glycol-
ysis (38). 18F-FDG PET was positive in VHL patients with 
urinary bladder PGLs (n = 3) but no metastatic disease (39). 
In 52 VHL patients, 18F-FDG PET indicated the presence of 
more lesions than MRI or 18F-DOPA PET. It was superior 
for lesions in the pancreas and kidney; however, 30% of ex-
trapancreatic lesions were seen only with 18F-DOPA PET and 
none of the other imaging techniques (40).
Since PHEOs/PGLs express to a high degree STRs type 2 
(higher than 80%), 68Ga-DOTATATE PET/CT shows better 
diagnostic accuracy than “classic” SRS in the evaluation of 
PHEO patients; this can be attributed to the higher sensitiv-
ity of  68Ga-DOTATATE PET/CT (due to the high-quality 
images obtained with superior contrast and spatial res-
olution, and the higher affinity for STRs) (41). However, 
functional imaging with DOTA-compounds may be ham-
pered by intense physiological uptake by the normal adre-
nal glands; small PHEOs or PGLs in VHL patients may be 
missed (20). In patients with VHL (n = 24) and gastroin-
testinal neuroendocrine tumors (but no reported PHEO/
PGL), biomarkers for plasma tumors correlated with 68Ga- 
DOTATATE-calculated tumor volume (25). In a case re-
port, 68Ga-DOTANOC PET/CT in a VHL patient detected 
both a cerebellar hemangioblastoma and a unilateral PHEO 
(42). In another case report, cerebellar lesions were found, 
but no PHEO (43).
Imaging with ST-R antagonists is an evolving domain: it 
has been used effectively for breast cancer (44) and pancreatic 
neuroendocrine tumors (45). In the future, they may be effec-
tively used for PHEOs/PGLs, since apparently these ligands 
show higher tumor uptake compared to ST-R analogues 
and permit better tumor visualization (46–48). Unrelated 
to PHEOs/PGLs, a novel PET tracer, [89Zr]-bevacizumab 
(which binds VEGF-A) has been tried in VHL patients, visu-
alizing hemangioblastomas (although these are benign non-
metastasizing tumors, if  undetected they may lead to severe 
neurological deficits and death (49)), renal cell carcinomas, 
and brain metastases (50).
Conclusion
Consensuses and guidelines suggest that metastatic and 
sporadic PHEOs/PGLs in VHL patients (as in patients 
with chromaffin tumors of yet unknown genotype) should 
be evaluated first with 18F-DOPA PET (21, 51). The func-
tional imaging of second choice is 123I-MIBG for PHEOs in 
VHL patients. 123I-MIBG, 68Ga-DOTATATE/DOTATOC/
DOTANOC PET/CT, or 18F-FDG PET/CT can be a second 
choice of functional imaging for PGLs in VHL patients (21). 
Additionally, in a very recent European Association of Nu-
clear Medicine guideline on the imaging of neuroendocrine 
tumors in general, including PGLs, preference is given to 
68Ga-labelled SRS PET/CT over 18F-FDG PET/CT (52).
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